All regulatory updates
148 results found
BAT/BEP expert meeting work programme includes planned updates to guidance to reflect newly listed POPs (MCCPs, LC‑PFCAs, UV‑328 exemptions; possible chlorpyrifos guidance)
An official Stockholm Convention BAT/BEP meeting page indicates an implementation work programme to update Best Available Techniques/Best Environmental Practices guidance to reflect recent Stockholm Convention outcomes: incorporating MCCPs into SCCPs-related guidance, including LC‑PFCAs in PFOS/PFOA-relevant guidance, updating UV‑328 BAT/BEP guidance reflecting COP-12 exemption amendments, and considering in June 2026 whether to develop BAT/BEP guidance for chlorpyrifos. For compliance teams, these updates can affect operational expectations for controlling releases and managing wastes/industrial processes linked to newly listed POPs and exemptions.
Nevada Board of Pharmacy issued notice proposing to add ethylphenidate and 2‑methyl AP‑237 to Schedule I (NAC 453.510) with hearing set for Dec 4, 2025
The Nevada State Board of Pharmacy published a public hearing notice and proposed regulation text to amend NAC 453.510 to add ethylphenidate and 2‑methyl AP‑237 to Schedule I under Nevada’s Uniform Controlled Substances Act implementation. The notice sets a public hearing for Dec. 4, 2025. (Note: a separate later Nevada Register informational statement indicates these substances were subsequently adopted into Schedule I; this record captures the earlier proposal and comment/hearing step.)
RMI publishes EMRT 2.1 Completion Guide with updated instructions and revision history (including mine list smelter selection guidance)
RMI released the EMRT 2.1 Completion Guide corresponding to EMRT revision 2.1. The guide provides authoritative instructions for completing the EMRT and includes a revision history noting guidance updates, including guidance for selecting smelters from the drop-down menu on the Mine List tab (Oct 17, 2025 entry) and prior guidance additions tied to the Apr 25, 2025 release. This is operationally relevant for compliance teams because it affects how suppliers are instructed to complete the template and how recipients validate completeness/consistency of Mine List and smelter selections.
RMI releases EMRT v2.1 and recommends it for the reporting year (template changes to scope notice, product list fields, and smelter/mine list tabs)
The Responsible Minerals Initiative (RMI), the governing body for the Extended Minerals Reporting Template (EMRT), released EMRT version 2.1 and states it is the recommended version for the reporting year. The EMRT v2.1 update includes structural/field changes that impact supplier survey collection and internal data validation, including: (1) an added notice of “Select Minerals/Metals in Scope,” (2) Product List updates adding “Requester Product Number” and “Requester Product Name,” and (3) updates to the Smelter List and Mine List tabs and to the Smelter Reference/Standard Smelter List content. Compliance teams using EMRT for customer due diligence requests should update internal templates, instructions, and validation checks to align to v2.1.
ECHA reports European Commission adopted EU-wide REACH restriction on PFAS in firefighting foams (3 Oct 2025)
ECHA Weekly reported that the European Commission adopted an EU-wide REACH restriction on PFAS in firefighting foams on 3 October 2025, including transition periods. Compliance teams for manufacturers, importers, distributors, and users of firefighting foams should assess affected PFAS-containing formulations, transition timelines, and downstream user communications to ensure continued market access and compliant substitution planning.
European Commission adopts EU-wide REACH restriction on PFAS in firefighting foams (reported by ECHA Weekly)
ECHA Weekly reported that the European Commission adopted an EU-wide REACH restriction on PFAS in firefighting foams. This creates binding EU controls on placing on the market and use of PFAS-containing firefighting foams (with transition periods referenced in the ECHA Weekly summary). Compliance teams in fire safety, airports, industrial sites, and foam manufacturers/importers should review the adopted restriction requirements, transition periods, and substitution/stock management obligations.
EPA issues Sept 30, 2025 primacy extension request templates for state adoption of the 2024 PFAS NPDWR
EPA published primacy extension request documents (memo/templates) to support states, territories, and tribes in requesting additional time to adopt the 2024 PFAS National Primary Drinking Water Regulation (NPDWR) into their primacy programs. This is an implementation support update for drinking-water regulators and utilities; compliance teams should monitor primacy adoption timelines and any associated state-level implementation schedules tied to the NPDWR.
EPA publishes primacy extension request templates to support PFAS NPDWR state implementation
EPA published implementation resources for the PFAS NPDWR, including templates intended to help primacy agencies request extensions for primacy revision actions. State primacy agencies and regulated water systems should use these materials to plan state adoption/primacy timelines and coordinate implementation planning.
57th ASEAN Economic Ministers’ Meeting statement confirms conclusion of ATIGA upgrade negotiations and target signing of 2nd Protocol to Amend ATIGA at 47th ASEAN Summit (Oct 2025)
The Joint Media Statement of the 57th ASEAN Economic Ministers’ Meeting (23 September 2025) reports that negotiations to upgrade the ASEAN Trade in Goods Agreement (ATIGA) were concluded on 24 May 2025 and that ASEAN targeted signing the 2nd Protocol to Amend ATIGA at the 47th ASEAN Summit in October 2025. For trade compliance teams, this signals forthcoming changes to ASEAN’s trade-in-goods rules, including coverage of emerging issues (as described in the statement) and inclusion of an Alternative Dispute Resolution mechanism for ASEAN trade-in-goods disputes. The statement does not confirm entry-into-force or compliance dates.
57th AEM statement notes signing of Protocol to amend ASEAN Sectoral MRA for GMP inspection of medicinal product manufacturers (entry-into-force pending)
The 57th AEM Joint Media Statement indicates that ASEAN signed a Protocol to amend the ASEAN Sectoral Mutual Recognition Arrangement (MRA) for Good Manufacturing Practice (GMP) inspection of manufacturers of medicinal products, and refers to expected entry-into-force for implementation (without providing a date). This is relevant for pharmaceutical manufacturing and regulatory affairs teams because an updated MRA can change how GMP inspections and recognition of inspection outcomes are conducted across ASEAN, potentially affecting inspection planning, audit readiness, and market authorization support.
ASEAN Authorised Economic Operator MRA implemented by six Member States; full implementation across all ten targeted by Dec 2025
The 57th AEM Joint Media Statement reports that the ASEAN Authorised Economic Operator Mutual Recognition Arrangement (AAMRA) had been implemented by six ASEAN Member States since 28 February 2025, and that ASEAN aimed for full implementation across all ten Member States by December 2025. This is relevant for customs/trade compliance programmes as it indicates expanded mutual recognition of AEO status and related facilitation benefits, with a stated regional target timeline for broader rollout.
EPA proposes revisions to procedures for chemical risk evaluation under TSCA (Federal Register proposal dated Sept. 23, 2025)
EPA issued a proposed rule to amend procedures for conducting chemical risk evaluations for existing chemicals under TSCA. This proposal would revise the risk evaluation framework and could affect how companies plan for risk evaluation scope, data submissions, use categorization, and downstream risk management implications. Compliance teams should review the proposal and consider participating in the public comment process for impacts to ongoing and future TSCA risk evaluations.
NIOSH revises CBRN Respiratory Protection Handbook; CBRN APR Protection List expanded and fit-testing statement corrected
NIOSH published an updated/revised CBRN Respiratory Protection Handbook (Publication 2025-111). The update expands the CBRN APR Protection List (described as increasing from 139 to 286 hazards) and includes corrections/clarifications regarding fit testing references (clarifying OSHA’s continued acceptance of qualitative fit testing for positive pressure tight-fitting respirators and NFPA’s identification of quantitative fit testing for positive pressure respirator wearers). This matters for emergency response and CBRN respiratory protection program planning, hazard coverage assumptions, and fit-testing communications aligned to NIOSH/OSHA/NFPA expectations.
ECHA sets 2026 milestones and plans spring 2026 consultation on SEAC draft opinion for proposed EU-wide PFAS restriction
ECHA communicated process milestones for the proposed EU-wide REACH restriction on PFAS, including that SEAC expects to agree its draft opinion around March 2026 and that ECHA plans a 60‑day consultation in spring 2026 on the SEAC draft opinion. ECHA also indicates RAC opinion adoption is expected around March 2026 and that SEAC’s final opinion is expected by end of 2026. For companies placing PFAS-containing substances/mixtures/articles on the EU market, this signals a near-term opportunity/need to submit socio-economic and use information during the spring 2026 consultation, and to monitor forthcoming RAC/SEAC opinions that will shape the European Commission’s eventual restriction decision.
ASEAN Plan of Action in Combatting Transnational Crime (2026–2035) adopted (enhanced cross-border enforcement cooperation priorities)
ASEAN adopted the ASEAN Plan of Action in Combatting Transnational Crime (2026–2035) at the 19th AMMTC (10 September 2025). Although not a product standard, it is an official ASEAN framework that signals strengthened regional enforcement cooperation and coordination priorities (e.g., on transnational crime themes) and encourages review/harmonisation of relevant national laws and practices. Compliance teams (AML/fraud/cyber/investigations) may use it as an indicator of increased cross-border cooperation and potential alignment of enforcement approaches among ASEAN Member States.
IDFPR Compliance Capsule reiterates pharmacist cannot refuse to fill a valid controlled-substance prescription solely because it is not electronic (EPCS) and pharmacists are not responsible for enforcing prescriber EPCS compliance
In its Fall 2025 Compliance Capsule newsletter, IDFPR highlights 720 ILCS 570/311.6(e), emphasizing that a pharmacist may not refuse to fill a valid controlled-substance prescription solely because it is not prescribed electronically, and that pharmacists are not responsible for enforcing prescriber compliance with electronic prescribing of controlled substances (EPCS) requirements. This guidance is operationally relevant for pharmacies’ dispensing policies, staff training, and refusal-to-fill procedures, especially where workflows have been configured to reject non-electronic controlled-substance prescriptions.
ECHA announces target to complete scientific evaluation of proposed EU-wide PFAS restriction by end of 2026
ECHA published a timeline update indicating that its committees aim to complete the scientific evaluation of the proposed EU-wide REACH restriction on PFAS by the end of 2026. This is a procedural milestone (not an adopted restriction) that helps companies forecast when RAC/SEAC opinions may be finalized and when the European Commission could proceed toward a draft restriction decision, enabling earlier planning for potential substitution, essential-use justifications, and stakeholder participation.
ECHA publishes updated PFAS restriction proposal dossier to support ongoing committee evaluation
ECHA announced publication of an updated REACH restriction proposal dossier for PFAS (updated background/proposal materials) as part of the ongoing evaluation of the proposed EU-wide restriction. For compliance teams, the updated dossier can change understanding of scope, derogations, and sector-specific considerations used in RAC/SEAC assessment and provides updated reference material to support company impact assessments and consultation preparation.
EPA releases latest public TSCA Inventory update and notes next regular update planned for winter 2026
EPA announced availability of the latest update to the public (non-confidential) TSCA Inventory as part of its biannual posting cycle, including updates to inventory totals and associated data elements (e.g., commercial activity, unique identifier data, regulatory flags). EPA also notes the next regular update is planned for winter 2026. Compliance teams should refresh internal inventory reference datasets and re-check substance listing status and applicable flags used to support TSCA Inventory determinations.
NIOSH issues July 17, 2025 notice adding three hazardous drugs (MSHI) to Table 1 of the 2024 hazardous drug list
NIOSH posted a notice dated July 17, 2025 stating that three drugs with manufacturer’s special handling information (MSHI) are considered included in Table 1 of the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024: datopotamab deruxtecan (Datroway®), treosulfan (Grafapex™), and telisotuzumab vedotin (Emrelis™). Healthcare organizations and entities aligning hazardous drug handling programs (e.g., under USP <800>) should evaluate whether these agents are handled onsite and update inventories, risk assessments, SOPs, training, engineering controls/PPE, labeling, and waste procedures accordingly.